title: Oocyst shedding in cats vaccinated by the nasal and rectal routes with crude rhoptry proteins of Toxoplasma gondii.
abstract: During this study, cats were immunized by the intranasal and rectal routes with crude rhoptry proteins of Toxoplasma gondii admixed with Quil-A. Twenty-five domestic short hair cats divided into five groups (n=5) were used during this evaluation: G1 and G3 cats received 200 μg of the rhoptry proteins with Quil-A (20 μg) by the intranasal and rectal routes, respectively; G2 and G4 cats received bovine serum albumin (BSA, 200 μg/dose) with Quil-A (20 μg); and G5 animals served as unvaccinated controls. All treatments were performed at days 0, 21, 42, and 63. The challenge was done with 800 cysts of the ME49 of T. gondii strain at day 70 (challenge day). The serum IgG, IgM, IgA, and fecal IgA antibody levels were evaluated by using the indirect enzyme-linked immunosorbent assay (ELISA). Some animals produced antibody levels beyond cut-off; however, two animals from G1 (OD(mean)=0.308, OD(cut-off)=0.200) and three from G3 (OD(mean)=0.254) demonstrated IgG levels on being challenged, with similar results occurring in two cats from G1 to IgM (OD(mean)=0.279, OD(cut-off)=0.200). Fecal IgA levels were detected in all G1 cats (OD(mean)=0.330, OD(cut-off)=0.065), and in one cat from G3 (OD(mean)=0.167). The serum and fecal humoral immune responses did not correlate with oocyst shedding. Oocyst shedding varied from 98.4% (G1), 87.5% (G2), 53.0% (G3), to 58% (G4), and was lower than that of G5 cats. The prepatent period of cats vaccinated intranasally (G1) was reduced from 6-9.6 to 2.8 days, suggesting protection of environmental contamination, considering cats as the primary source of contamination. The intranasally and rectally administered rhoptry vaccines were able to partially protect cats against T. gondii cysts on being challenged; however, the intranasal method of vaccination yielded better results relative to the rectal route.
authors.affiliation: Protozoology Laboratory, Departamento de Medicina Veterinária Preventiva, Universidade de Londrina-UEL, Londrina, PR, Brazil.
authors.forename: Dauton Luiz
authors.initials: DL
authors.lastname: Zulpo
authors.forename: Selwyn Arlington
authors.initials: SA
authors.lastname: Headley
authors.forename: Luciane
authors.initials: L
authors.lastname: Biazzono
authors.forename: Ivo Alexandre Leme
authors.initials: IA
authors.lastname: da Cunha
authors.forename: Michelle
authors.initials: M
authors.lastname: Igarashi
authors.forename: Luiz Daniel
authors.initials: LD
authors.lastname: de Barros
authors.forename: Alessandra
authors.initials: A
authors.lastname: Taroda
authors.forename: Sérgio Tosi
authors.initials: ST
authors.lastname: Cardim
authors.forename: Alexey Leon Gomel
authors.initials: AL
authors.lastname: Bogado
authors.forename: Italmar Teodorico
authors.initials: IT
authors.lastname: Navarro
authors.forename: João Luis
authors.initials: JL
authors.lastname: Garcia
mesh_terms: D000281:Administration, Intranasal / Q000662:veterinary; D000285:Administration, Rectal; D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis / Q000097:blood; D002371:Cat Diseases / Q000469:parasitology / Q000517:prevention & control*; D002415:Cats; D005243:Feces / Q000469:parasitology; D005260:Female; D007071:Immunoglobulin A, Secretory / Q000032:analysis; D007136:Immunoglobulins / Q000096:biosynthesis / Q000097:blood; D007422:Intestines / Q000276:immunology; D007700:Kinetics; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D051379:Mice; D015800:Protozoan Proteins / Q000276:immunology*; D016052:Protozoan Vaccines / Q000008:administration & dosage* / Q000276:immunology; D011897:Random Allocation; D014122:Toxoplasma / Q000276:immunology*; D014124:Toxoplasmosis, Animal / Q000469:parasitology / Q000517:prevention & control*; D014611:Vaccination / Q000379:methods / Q000662:veterinary
chemical_list: D000913:Antibodies, Protozoan; D007071:Immunoglobulin A, Secretory; D007136:Immunoglobulins; D015800:Protozoan Proteins; D016052:Protozoan Vaccines